

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
Petitioner,

v.

BIOGEN MA INC.,
Patent Owner.

IPR2018-01403
U.S. Patent No. 8,399,514

PATENT OWNER'S AMENDED MANDATORY NOTICES

Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Biogen MA Inc. provides the following updated mandatory notices.

Patent Owner has updated Section II Related Matters to reflect the fact that the Federal Circuit issued its mandate in *FWP IP ApS v. Biogen MA Inc.*, No. 2017-2109 (Fed. Cir.) on January 9, 2019, after affirming the Board and denying Appellant's combined petition for panel rehearing and rehearing en banc on January 2, 2019. In particular, Patent Owner has deleted "*FWP IP ApS v. Biogen MA Inc.*, No. 2017-2109 (Fed. Cir.)" from Section II.

Patent Owner makes no other changes to the remaining Sections I, III, IV, and V originally provided on August 2, 2018.

I. Real Party-in-Interest - 37 C.F.R. § 42.8(b)(1)

The real party-in-interest is Biogen MA Inc., the owner of U.S. Patent No. 8,399,514 ("the '514 patent"). A corporate name change document was recorded in the U.S. Patent and Trademark Office on April 27, 2015 (reel 035507/frame 0541) and May 4, 2015 (reel 035571/frame 0926). Those documents changed the corporate name from Biogen Idec MA Inc. to Biogen MA Inc. The original assignment to Biogen Idec MA Inc. of U.S. patent application No. 13/372,426 that led to the '514 patent was recorded in the Office on May 3, 2012 (reel 028146/frame 0980).

II. Related Matters - 37 C.F.R. § 42.8(b)(2)

The '514 patent is currently involved in the following federal cases:

Biogen International GmbH and Biogen MA Inc. v. Amneal Pharmaceuticals LLC et al., C.A. No. 17-823-LPS (D. Del.) (Consolidated)

Biogen International GmbH and Biogen MA Inc. v. Mylan Pharmaceuticals Inc., C.A. No. 17-116-IMK (N.D. W.Va.)

The '514 patent has also been involved in the following proceedings before the PTAB:

Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01136 (McK)

Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01993 (RES)

Biogen MA Inc. v. Forward Pharma A/S, Intf. No. 106,023 (RES), *aff'd*, No. 2017-2109 (Fed. Cir. Oct. 24, 2018), *reh'g denied*, No. 2017-2109 (January 2, 2019)

The following U.S. Applications claim benefit of priority to the application that issued as the '514 patent: 13/767,014 (abandoned), 13/804,283 (abandoned), 14/718,962 (abandoned), 15/959,651 (pending), 15/983,837 (pending), and 15/988,578 (pending).

Patent Owner is not aware of any other related matters that would affect or be affected by this proceeding.

III. Lead and Back-up Counsel - 37 C.F.R. § 42.8(b)(3)

Lead Counsel	Back-Up Counsel
<p>Barbara C. McCurdy Reg. No. 32,120 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001 (202) 408-4047 barbara.mccurdy@finnegan.com</p>	<p>Erin M. Sommers Reg. No. 60,974 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001 (202) 408-4292 erin.sommers@finnegan.com</p> <p>Pier D. DeRoo Reg. No. 69,340 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001 (202) 408-4418 pier.deroo@finnegan.com</p>

IV. Power of Attorney - 37 C.F.R. § 42.10(b)

Pursuant to 37 C.F.R. § 42.10(b), Patent Owner confirms that a power of attorney for U.S. Application No. 13/372,426 (issued as the '514 patent) from Biogen MA Inc. to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (Customer Number 22,852), which includes Barbara C. McCurdy, Erin M. Sommers, and Pier D. DeRoo, was previously filed with the USPTO on April 27, 2015 in Interference No. 106,023. A copy was attached as Appendix A to Patent Owner's initial Mandatory Notices filed on August 2, 2018.

V. Service Information

Please send all correspondence to the lead counsel at the address shown above.

Under 37 C.F.R. § 42.6(e), Patent Owner consents to electronic service by e-mail to the following e-mail addresses:

barbara.mccurdy@finnegan.com;

erin.sommers@finnegan.com; and

pier.deroo@finnegan.com.

Respectfully submitted,

Dated: January 22, 2019

By: / Barbara C. McCurdy /
Barbara C. McCurdy, Reg. No. 32,120
Finnegan, Henderson, Farabow, Garrett
& Dunner, LLP
901 New York Avenue, NW
Washington, DC 20001-4413
(202) 408-4047
Counsel for Patent Owner

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.